HRP20191181T1 - 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma - Google Patents
7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma Download PDFInfo
- Publication number
- HRP20191181T1 HRP20191181T1 HRP20191181TT HRP20191181T HRP20191181T1 HR P20191181 T1 HRP20191181 T1 HR P20191181T1 HR P20191181T T HRP20191181T T HR P20191181TT HR P20191181 T HRP20191181 T HR P20191181T HR P20191181 T1 HRP20191181 T1 HR P20191181T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- cancer agent
- hydrochloride salt
- butanol
- hcl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779828P | 2013-03-13 | 2013-03-13 | |
| US201361904718P | 2013-11-15 | 2013-11-15 | |
| EP14775569.8A EP2968294B1 (en) | 2013-03-13 | 2014-03-13 | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer |
| PCT/US2014/025885 WO2014160130A1 (en) | 2013-03-13 | 2014-03-13 | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191181T1 true HRP20191181T1 (hr) | 2019-10-04 |
Family
ID=51527915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191181TT HRP20191181T1 (hr) | 2013-03-13 | 2014-03-13 | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9265765B2 (https=) |
| EP (2) | EP3572083A1 (https=) |
| JP (3) | JP6446025B2 (https=) |
| KR (2) | KR102438135B1 (https=) |
| CN (2) | CN119954807A (https=) |
| AU (3) | AU2014244117B2 (https=) |
| BR (1) | BR112015023256A2 (https=) |
| CA (2) | CA2905037C (https=) |
| CY (1) | CY1121735T1 (https=) |
| DK (1) | DK2968294T3 (https=) |
| EA (1) | EA037937B1 (https=) |
| ES (1) | ES2734568T3 (https=) |
| HR (1) | HRP20191181T1 (https=) |
| HU (1) | HUE044238T2 (https=) |
| IL (2) | IL241452B (https=) |
| LT (1) | LT2968294T (https=) |
| ME (1) | ME03470B (https=) |
| MX (2) | MX2015012636A (https=) |
| NZ (2) | NZ751509A (https=) |
| PL (1) | PL2968294T3 (https=) |
| PT (1) | PT2968294T (https=) |
| RS (1) | RS59013B1 (https=) |
| SG (2) | SG10201808496VA (https=) |
| SI (1) | SI2968294T1 (https=) |
| SM (1) | SMT201900384T1 (https=) |
| WO (1) | WO2014160130A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4335511T3 (fi) | 2011-04-29 | 2026-01-29 | Penn State Res Found | Pienimolekyylinen normaalien ja kasvainsolujen trail-geenin indusointi syöpähoitona |
| WO2014160130A1 (en) | 2013-03-13 | 2014-10-02 | Oncoceutics, Inc. | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| ES2812208T3 (es) | 2013-03-14 | 2021-03-16 | Bristol Myers Squibb Co | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso |
| IL311202A (en) * | 2013-11-15 | 2024-05-01 | Oncoceutics Inc | 7-Benzyl-4-(2-methylbenzyl)-2, 4, 6, 7, 8, 9-hexahydroimidazo [1,2-A] pyrido[3,4-E] pyrimidine-5(1H)one, its salts and methods Use |
| AU2015228372B2 (en) | 2014-03-12 | 2018-05-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| LT3662910T (lt) * | 2014-03-31 | 2024-12-27 | The Scripps Research Institute | Trail geno indukcijai skirtas farmakoforas |
| WO2016123571A1 (en) * | 2015-01-30 | 2016-08-04 | Oncoceutics Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy |
| CN104860948B (zh) | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
| HUE044698T2 (hu) | 2015-08-17 | 2019-11-28 | Kura Oncology Inc | Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal |
| KR20170037260A (ko) | 2015-09-25 | 2017-04-04 | 현대자동차주식회사 | 차량용 배터리 시스템 및 그 제어 방법 |
| PL3408298T3 (pl) | 2016-01-29 | 2025-03-31 | Oncoceutics, Inc. | Modulacja przez imiprydony receptora sprzężonego z białkiem g (gpcr) |
| EP3423105B1 (en) | 2016-03-02 | 2021-05-05 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
| KR20170110520A (ko) * | 2016-03-23 | 2017-10-11 | 고려대학교 산학협력단 | mTOR 억제제 및 N-아세틸시스테인을 포함하는 간섬유화 억제용 조성물 |
| EP3439642A4 (en) * | 2016-04-06 | 2019-11-13 | Noxopharm Limited | IMPROVEMENTS IN RADIOTHERAPY |
| AU2017247008B2 (en) | 2016-04-06 | 2022-04-07 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
| WO2018031987A1 (en) * | 2016-08-12 | 2018-02-15 | Nanjing Gator Meditech Company, Ltd. | Protein kinase regulators |
| JP2019534290A (ja) | 2016-11-03 | 2019-11-28 | クラ オンコロジー， インコーポレイテッド | 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤 |
| US11576912B2 (en) | 2017-01-04 | 2023-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Target genes in MYC-driven neoplasia |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| US10172862B2 (en) | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
| IT201800004082A1 (it) * | 2018-03-29 | 2019-09-29 | Berlin Chemie Ag | Composizioni farmaceutiche antitumorali per terapia combinata |
| US20200046703A1 (en) * | 2018-08-09 | 2020-02-13 | Asymmetric Therapeutics, Llc | Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
| WO2020147842A1 (zh) * | 2019-01-18 | 2020-07-23 | 南京明德新药研发有限公司 | 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用 |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| MY209389A (en) * | 2019-11-28 | 2025-07-07 | Inxmed Nanjing Co Ltd | Use of bi853520 in cancer treatment |
| JP7582694B2 (ja) | 2020-01-10 | 2024-11-13 | イミューニヤリング コーポレーション | Ｍｅｋ阻害剤及びその治療的使用 |
| EP4125870A1 (en) | 2020-03-30 | 2023-02-08 | Noxopharm Limited | Methods for the treatment of inflammation associated with infection |
| CN117599041B (zh) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途 |
| EP4684834A1 (de) | 2024-07-26 | 2026-01-28 | BRIU GmbH | Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2150062A1 (de) * | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung |
| US4642345A (en) | 1980-08-14 | 1987-02-10 | Mead Johnson & Company | 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones |
| US7635690B2 (en) | 1999-01-22 | 2009-12-22 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
| AU2003217961B2 (en) | 2002-03-08 | 2008-02-28 | Signal Pharmaceuticals, Llc | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| US20080221135A1 (en) | 2005-05-13 | 2008-09-11 | Bristol-Myers Squibb Company | Combination therapy |
| EP2350641B1 (en) * | 2008-09-22 | 2014-09-24 | Amgen Inc. | A combination of a tnf alpha inhibitor, an iap inhibitor and a trail receptor agonist for use in treating cancer |
| NZ593343A (en) | 2008-12-11 | 2013-04-26 | Abraxis Bioscience Llc | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor |
| US9724337B2 (en) | 2009-04-21 | 2017-08-08 | University Of Kentucky Research Foundation | AG-205 for the treatment of breast cancer |
| DE102010014426A1 (de) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| FI4335511T3 (fi) * | 2011-04-29 | 2026-01-29 | Penn State Res Found | Pienimolekyylinen normaalien ja kasvainsolujen trail-geenin indusointi syöpähoitona |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| WO2014160130A1 (en) | 2013-03-13 | 2014-10-02 | Oncoceutics, Inc. | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
| LT3662910T (lt) | 2014-03-31 | 2024-12-27 | The Scripps Research Institute | Trail geno indukcijai skirtas farmakoforas |
-
2014
- 2014-03-13 WO PCT/US2014/025885 patent/WO2014160130A1/en not_active Ceased
- 2014-03-13 CN CN202510107155.3A patent/CN119954807A/zh active Pending
- 2014-03-13 SM SM20190384T patent/SMT201900384T1/it unknown
- 2014-03-13 LT LTEP14775569.8T patent/LT2968294T/lt unknown
- 2014-03-13 KR KR1020157028393A patent/KR102438135B1/ko active Active
- 2014-03-13 AU AU2014244117A patent/AU2014244117B2/en not_active Ceased
- 2014-03-13 SI SI201431257T patent/SI2968294T1/sl unknown
- 2014-03-13 NZ NZ751509A patent/NZ751509A/en active IP Right Revival
- 2014-03-13 US US14/208,657 patent/US9265765B2/en active Active
- 2014-03-13 SG SG10201808496VA patent/SG10201808496VA/en unknown
- 2014-03-13 MX MX2015012636A patent/MX2015012636A/es active IP Right Grant
- 2014-03-13 PT PT14775569T patent/PT2968294T/pt unknown
- 2014-03-13 HR HRP20191181TT patent/HRP20191181T1/hr unknown
- 2014-03-13 CA CA2905037A patent/CA2905037C/en active Active
- 2014-03-13 JP JP2016501988A patent/JP6446025B2/ja active Active
- 2014-03-13 ME MEP-2019-197A patent/ME03470B/me unknown
- 2014-03-13 HU HUE14775569 patent/HUE044238T2/hu unknown
- 2014-03-13 EP EP19171477.3A patent/EP3572083A1/en not_active Withdrawn
- 2014-03-13 NZ NZ711948A patent/NZ711948A/en unknown
- 2014-03-13 CN CN201480022856.7A patent/CN105530937A/zh active Pending
- 2014-03-13 SG SG11201507247WA patent/SG11201507247WA/en unknown
- 2014-03-13 DK DK14775569.8T patent/DK2968294T3/da active
- 2014-03-13 EP EP14775569.8A patent/EP2968294B1/en active Active
- 2014-03-13 RS RS20190874A patent/RS59013B1/sr unknown
- 2014-03-13 EA EA201591715A patent/EA037937B1/ru unknown
- 2014-03-13 CA CA3204801A patent/CA3204801A1/en active Pending
- 2014-03-13 BR BR112015023256A patent/BR112015023256A2/pt not_active Application Discontinuation
- 2014-03-13 ES ES14775569T patent/ES2734568T3/es active Active
- 2014-03-13 PL PL14775569T patent/PL2968294T3/pl unknown
- 2014-03-13 KR KR1020227029471A patent/KR20220123335A/ko not_active Ceased
-
2015
- 2015-09-10 IL IL241452A patent/IL241452B/en active IP Right Grant
- 2015-09-11 MX MX2019013643A patent/MX2019013643A/es unknown
-
2018
- 2018-06-22 JP JP2018119005A patent/JP2018184411A/ja active Pending
-
2019
- 2019-03-19 AU AU2019201896A patent/AU2019201896A1/en not_active Abandoned
- 2019-07-01 CY CY20191100687T patent/CY1121735T1/el unknown
-
2020
- 2020-06-23 IL IL275623A patent/IL275623A/en unknown
- 2020-07-01 JP JP2020114024A patent/JP2020172510A/ja active Pending
- 2020-09-14 AU AU2020233606A patent/AU2020233606A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191181T1 (hr) | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma | |
| AU2020200692C1 (en) | Heterocyclic amides useful as protein modulators | |
| CN111712498B (zh) | 作为prmt5抑制剂的取代的二环杂环化合物 | |
| Mirhosseini-Eshkevari et al. | Novel bronsted acidic ionic liquids confined in UiO-66 nanocages for the synthesis of dihydropyrido [2, 3-d] pyrimidine derivatives under solvent-free conditions | |
| JP6952695B2 (ja) | インフルエンザウイルス複製の阻害剤、その適用方法および使用 | |
| DK2655375T3 (en) | PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF | |
| CA2907502A1 (en) | Benzimidazolone derivatives as bromodomain inhibitors | |
| PH12013502445A1 (en) | Pyridin-2 (1h) -one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases | |
| CN106946876B (zh) | 一种唑吡坦的制备方法 | |
| EP2863902A1 (en) | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using pi3 kinase inhibitors | |
| TW201402577A (zh) | 包含經取代嗎福啉之新穎２，３－二氫－１Ｈ－咪唑并｛１，２－ａ｝嘧啶－５－酮及１，２，３，４－四氫嘧啶并｛１，２－ａ｝嘧啶－６－酮衍生物，其製備及其醫療用途 | |
| HRP20160495T1 (hr) | Morfolinilbenzotriazini za uporabu u terapiji raka | |
| Devi et al. | In (OTf) 3 catalysed an expeditious synthesis of β-carboline–imidazo [1, 2-a] pyridine and imidazo [1, 2-a] pyrazine conjugates | |
| Megbas Al-Ghamdi et al. | Synthesis and Antitumor Activities of 4H-Pyrano [3, 2-h] quinoline-3-carbonitrile, 7H-Pyrimido [4', 5': 6, 5] pyrano [3, 2-h] quinoline, and 14HPyrimido [4', 5': 6, 5] pyrano [3, 2-h][1, 2, 4] triazolo [1, 5-c] quinoline Derivatives | |
| AU2013282317A1 (en) | Cyanoguanidines and their use as antiviral agents | |
| Yong et al. | Synthesis and preliminarily cytotoxicity to A549, HCT116 and MCF-7 cell lines of thieno [2, 3-d] pyrimidine derivatives containing isoxazole moiety | |
| EP2714667B1 (en) | Aminooxazole inhibitors of cyclin dependent kinases | |
| CN108239075B (zh) | 喹唑啉类化合物及其制备方法、用途和药物组合物 | |
| CN106866661B (zh) | 一种氰甲基化咪唑并吡啶类化合物的制备方法 | |
| Pan et al. | Synthesis of 4-phenylthieno [2, 3-e][1, 2, 4] triazolo [4, 3-a] pyrimidine-5 (4H)-one derivatives and evaluation of their anti-inflammatory activity | |
| Mityuk et al. | Efficient route for the synthesis of diverse heteroannelated 5-cyanopyridines | |
| CN116217566B (zh) | 一种抗凋亡蛋白bcl-2抑制剂、药物组合物及其应用 | |
| Zhou et al. | Synthesis and in vitro anti-inflammatory activity of pyrrolo [1, 2-a] pyrazines via Pd-catalyzed intermolecular cyclization reaction | |
| Prabha et al. | Benzoquinoline amines–Key intermediates for the synthesis of angular and linear dinaphthonaphthyridines | |
| CN106146524A (zh) | 呋喃并[3，4-d]嘧啶-4，5(3H，7H)-二酮类化合物及其制备方法 |